Baird Maintains ResMed(RMD.US) With Buy Rating, Maintains Target Price $280
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Resmed (RMD)
BofA Securities Maintains ResMed(RMD.US) With Buy Rating, Announces Target Price $270
Resmed Poised for Growth Amid Rising OSA Diagnosis and Market Opportunity: Buy Rating Reaffirmed With Increased Price Objective
ResMed (NYSE:RMD) Eyes Growth With Board Expansion and Solid Earnings Despite Freight Cost Challenges
ResMed Analyst Ratings
Baird Initiates ResMed(RMD.US) With Buy Rating, Announces Target Price $280
ResMed Inc. (NYSE:RMD) Is a Favorite Amongst Institutional Investors Who Own 74%
ResMed (NYSE:RMD) Shareholders Have Earned a 14% CAGR Over the Last Five Years
Is ResMed Stock Outperforming the S&P 500?
Top Gap Ups and Downs on Wednesday: TM, ETN, IBN and More
Why ResMed Stock Tumbled by 5% Today
S&P 500 Gains and Losses Today: ResMed Drops as Weight-Loss Drugs Threaten Demand
Equity Markets Fall After 50-Basis-Point Fed Rate Cut
Wall Street Today | FOMC Cuts Bring Spiking Highs
US Equities Markets End Lower Wednesday After FOMC Cuts Rates
ResMed Slips as Wolfe Downgrades on GLP-1 Threat From Lilly
These Are the Mid-caps That Could Perform Best During 'Downturn' Regimes – BofA
Sector Update: Health Care Stocks Advance in Afternoon Trading
Vivos Surges on FDA Nod for Pediatric Sleep Apnea Device